FIGURE 3.

Administration of oroxylin A enhanced the hippocampal BDNF signaling cascade in both the CUMS-treated and CRS-treated mice. (A and C) Representative western blotting images and corresponding analyses show that mice in the (CUMS + oroxylin A)-treated and (CUMS + paroxetine)-treated groups had evidently higher protein levels of BDNF, pTrkB and pCREB in the hippocampus than mice in the (CUMS + vehicle)-treated group. (B and D) Representative images of western blotting and corresponding analyses indicated that mice in the (CRS + oroxylin A)-treated and (CRS + paroxetine)-treated groups also had remarkably higher protein levels of BDNF, pTrkB and pCREB in the hippocampus than mice in the (CRS + vehicle)-treated group. All data are displayed as means ± S.E.M. (n = 6); ^** p < 0.01 vs. Vehicle; ^## p < 0.01 vs. (CUMS + Vehicle) or (CRS + Vehicle). The statistical comparisons were achieved by (Two-way ANOVA + Bonferroni’s test).